Randomized, double blind, placebo-controlled clinical trial to evaluate the lymphagogue effect and clinical efficacy of calcium dobesilate in chronic venous disease

Angiology

Volumn 59, Issue 3, 2008, Pages 352-356

  Flota Cervera, Fernando ^a   Flota Ruiz, Cintia ^a   Treviño, Carlos ^b   Berber, Arturo ^b,c  

^a Centro de Diagnostico de Enfermedades Cardiovasculares   (Mexico)

^b GRÜNENTHAL GMBH   (Germany)

^c NONE   (Mexico)

Author keywords

Calcium dobesilate; Chronic venous disease; Edema; Lymph; Lymphogammagraphy

Indexed keywords

DOBESILATE CALCIUM; PLACEBO;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; FEMALE; HUMAN; LYMPH FLOW; LYMPHEDEMA; MALE; PHYSICAL EXAMINATION; PLETHYSMOGRAPHY; RANDOMIZED CONTROLLED TRIAL; RASH; VEIN DISEASE;

ADMINISTRATION, ORAL; CALCIUM DOBESILATE; CAPSULES; CARDIOVASCULAR AGENTS; CHRONIC DISEASE; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; EDEMA; FEMALE; HUMANS; LOWER EXTREMITY; LYMPH; LYMPHATIC SYSTEM; LYMPHOGRAPHY; MALE; MIDDLE AGED; TREATMENT OUTCOME; VENOUS INSUFFICIENCY;

EID: 44849127229     PISSN: 00033197     EISSN: None     Source Type: Journal    
DOI: 10.1177/0003319707305407     Document Type: Article

References (22)

1. Nicolaides AN Cardiovascular Disease Educational and Research Trust; European Society of Vascular Surgery; the International Angiology Scientific Activity Congress Organization; International Union of Angiology; Union Internationale de Phlebologie at the Abbaye des Vaux de Cernay. Investigation of chronic venous insufficiency: a consensus statement (France, March 5-9, 1997). Circulation. 2000 ; 102: E126 - E163.
2. Beebe-Dimmer JL, Pfeifer JR, Engle JS, Schottenfeld D. The epidemiology of chronic venous insufficiency and varicose veins. Ann Epidemiol. 2005 ; 15: 175-184.
3. Brand FN, Dannenberg AL, Abbott RD, Kannel WB The epidemiology of varicose veins: the Framingham Study. Am J Prev Med. 1988 ; 4: 96-101.
4. Hume M. A venous renaissance ? J Vasc Surg. 1992 ; 15: 947-951.
5. Ramelet AA, Boisseau MR, Allegra C., et al. Veno-active drugs in the management of chronic venous disease. An international consensus statement: current medical position, prospective views and final resolution. Clin Hemorheol Microcirc. 2005 ; 33: 309-319.
6. Martinez MJ, Bonfill X., Moreno RM, Vargas E., Capellà D. Phlebotonics for venous insufficiency. Cochrane Database Syst Rev. 2005 ;(3). CD003229, doi:10.1002/14651858.CD003229.
7. Garay RP, Hannaert P., Chiavaroli C. Calcium dobesilate in the treatment of diabetic retinopathy. Treat Endocrinol. 2005 ; 4: 221-232.
8. Tejerina T., Ruiz E. Calcium dobesilate: pharmacology and future approaches. Gen Pharmacol. 1998 ; 31: 357-360.
9. Brunet J., Farine JC, Garay RP, Hannaert P. Angioprotective action of calcium dobesilate against reactive oxygen species-induced capillary permeability in the rat. Eur J Pharmacol. 1998 ; 358: 213-220.
10. Suschek C., Kolb H., Kolb-Bachofen V. Dobesilate enhances endothelial nitric oxide synthase-activity in macro- and microvascular endothelial cells. Br J Pharmacol. 1997 ; 122: 1502-1508.
11. Falkay G., Kovacs L. Calcium dobesilate (Doxium) as a prostaglandin synthetase inhibitor in pregnant human myometrium in vitro. Experientia. 1984 ; 40: 190-191.
12. Casley-Smith JR, Casley-Smith JR The effects of calcium dobesilate on acute lymphedema (with and without macrophages), and on burn edema. Lymphology. 1985 ; 18: 37-45.
13. Casley-Smith JR The influence of tissue hydrostatic pressure and protein concentration on fluid and protein uptake by diaphragmatic initial lymphatics; effect of calcium dobesilate. Microcirc Endothelium Lymphatics. 1985 ; 2: 385-415.
14. Piller NB The lymphogogue action of calcium dobesilate on the flow of lymph from the thoracic duct of anesthetized and mobile guinea pigs. Lymphology. 1988 ; 21: 124-127.
15. Lameynardie S., Chiavaroli C., Travo P., Garay RP, Parés- Herbuté N. Inhibition of choroidal angiogenesis by calcium dobesilate in normal Wistar and diabetic GK rats. Eur J Pharmacol. 2005 ; 510: 149-156.
16. Rota R., Chiavaroli C., Garay RP, Hannaert P. Reduction of retinal albumin leakage by the antioxidant calcium dobesilate in streptozotocin-diabetic rats. Eur J Pharmacol. 2004 ; 495: 217-224.
17. Widmer L., Biland L., Barras JP Doxium 500 in chronic venous insufficiency: a double-blind placebo controlled multicentre study. Int Angiol. 1990 ; 9: 105-110.
18. Pecchi S., De Franco V., Damiani P., Guerrini M., Di Perri T. Calcium dobesilate in the treatment of primary venous insufficiency of the lower limbs. A double-blind clinical study. Clin Ter. 1990 ; 132: 409-417.
19. Jaeger K., the CVI Study Group. Efficacy and safety of doxium in chronic venous insufficiency: double-blind, placebo-controlled multicentre study. Int Angiol. 2001 ; 20 (Suppl 1). 239.
20. Allain H., Ramelet AA, Polard E., Bentue-Ferrer D. Safety of calcium dobesilate in chronic venous disease, diabetic retinopathy and haemorrhoids. Drug Saf. 2004 ; 27: 649-660.
21. Widmer LK Peripheral Venous Disorders. Prevalence and Sociomedical Importance. Basel Study III. Bern, Switzerland: Hans Huber ; 1978.
22. Espinosa JD, Giannone CA Tratamiento de la insuficiencia venosa cronica con dobesilato de calcio. Un meta-analisis. Flebologia. 2001 ; 1: 15-20.